Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

PADO4 participants

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group reviews medium-term and long-term priorities for antiretroviral drug development to guide industry and other stakeholders on formulations most needed for low-income and middle-income countries. The group convened in December, 2018, to assess progress since the previous meeting and update the list of priority formulations. Issues relating to drug optimisation for neonatal prophylaxis and paediatric treatment, and those relating to the investigation of novel antiretrovirals in adolescents and pregnant and lactating women were also discussed. Continued focus on identifying, prioritising, and providing access to optimal antiretroviral formulations suitable for infants, children, and adolescents is key to ensuring that global HIV treatment targets can be met.

Original languageEnglish (US)
Pages (from-to)e623-e631
JournalThe Lancet HIV
Issue number9
StatePublished - Sep 2019

ASJC Scopus subject areas

  • Epidemiology
  • Immunology
  • Infectious Diseases
  • Virology


Dive into the research topics of 'Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list'. Together they form a unique fingerprint.

Cite this